U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07053904) titled 'Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors' on June 27.
Brief Summary: The goal of this clinical trial is to learn the safety of sequential treatment with P1101 and P1801 in advanced solid tumors. It will also learn the maximum tolerated dose (MTD) of P1801. The main questions it aims to answer are:
To evaluate the safety and tolerability of sequential treatment with P1101 and P1801 in patients with advanced solid tumors.
To determine the maximum tolerated dose (MTD) of P1801.
Participants will:
Ttreated by 6 doses of P1101 once per 2 weeks (Q2W) at 450 mcg and then followed by the treatment with...